CTS originally communicated that Tampa will convert from the current Grifols Ultrio Plus NAT triplex assay (HIV 1/2, HBV and HCV), performed on the Tigris testing platform, to the -enhanced Ultrio Elite triplex assay performed on the Panther testing platform on July 13, 2020. The implementation date has been moved up to July 7th. Contact your Customer Service Manager if you have any questions!
On December 28, 2021, the FDA updated the emergency use authorization (EUA) for COVID-19 conva...
Josh Moon has been appointed Chief Operating Officer (COO) at Creative Testing Solutions (CTS), effe...
In 2016, the Procleix Panther instrument was introduced by Grifols in support of automated NAT ZIKA ...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
The FDA Guidance ZIKV video for the webinar held on 08/15/18 has been posted in the Wh...
Reminder - Five CTS Forms will be updated on Monday September 2, 2019. Some of the forms are posted ...